Modulating Wnt Signaling Pathway to Enhance Allograft Integration in Orthopedic Trauma Treatment
Abstract
The research project was designed to test a novel approach of modulating Wnt signaling pathway in the bone tissue repair by using monoclonal antibodies against sclerostin (Sost) and DKK-1 (donated by Amgen Inc., Thousand Oaks, CA under MTA). Since the previous annual report, the project has progressed at a rapid pace. We resolved all initial technical difficulties and successfully completed all the surgical procedures, harvested samples at prescribe time points and evaluated new bone formation at the allograft site using CT scans and partially completed mechanical testing. Data presented in report reveals statistically that use of anti-Sost or anti-Dkk-1 antibodies enhances new bone formation around the allograft over all time points. Anti-Dkk-1 antibody treatment also seems to be superior to anti-Sost treatment. Mechanical testing show increasing strength over time. We are in the process of finalizing the mechanical testing and histology. Data so far supports our hypothesis.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2013
- Accession Number
- ADA594157
Entities
People
- Amarjit S. Virdi
Organizations
- Rush University